# A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses

> **NCT04544826** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-77474462
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04544826
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-16
- **Primary completion:** 2021-08-05
- **Final completion:** 2021-08-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04544826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04544826, "A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04544826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*